A fentanyl vaccine is about to have its first major test

Just small An amount of fentanyl, equivalent to a few grains of sand, is enough to stop a person’s breathing. the Synthetic opioids It is tasteless, odorless, and invisible when mixed with other substances, and drug users are often unaware of its presence.

That’s why biotech entrepreneur Colin Gage aims to protect people from the deadly effects of the drug. In 2023, he became co-founder and CEO of ARMR Sciences to develop a vaccine against fentanyl. Now, the company is launching a trial to test its vaccine in humans for the first time. Goal: Prevent overdose deaths.

“It became very clear to me that when I evaluated the treatment landscape, everything that existed was reactionary,” Gage says. “I thought, why don’t we prevent this?”

Fifty times more powerful than heroin and 100 times more powerful than morphine, fentanyl was first approved by the Food and Drug Administration in 1968 as an intravenous pain reliever and anesthetic. It had the potential to be abused recognized even thenDoctors can only get it with the painkiller droperidol in a 50:1 ratio of droperidol to fentanyl.

Cheap to make and incredibly addictive, fentanyl is now found in street drugs and counterfeit pills because it enhances their effectiveness and lowers costs. This drug is the largest cause of overdose deaths in the United States and the leading cause of death for Americans aged 18 to 45 years.

Naloxone, known by the brand name Narcan, can quickly reverse overdoses caused by fentanyl and other opioids. The widespread distribution of the drug contributed to the occurrence of a Decreased by 24 percent in drug overdose deaths in the United States in 2024. It works by binding to opioid receptors throughout the body and displacing bound opioid molecules there.

But a vaccine like the one being developed by ARMR Sciences would be introduced even before a person encounters the drug. Gage likens it to a bulletproof vest or suit of armor, hence the company’s name. (It was previously registered as Ovax, but its name was changed in January). “This is something that could completely change the paradigm of how we deal with overdose, because it doesn’t require someone to hold the treatment on them,” Gage says.

Opioid vaccines were initially proposed in the 1970s, but after early attempts at heroin vaccines failed, much of the research was abandoned. The recent opioid epidemic has led to renewed interest, with With support from the US government.